Endothelial Cell Adhesion Molecules- (un)Attainable Targets for Nanomedicines

7Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Endothelial cell adhesion molecules have long been proposed as promising targets in many pathologies. Despite promising preclinical data, several efforts to develop small molecule inhibitors or monoclonal antibodies (mAbs) against cell adhesion molecules (CAMs) ended in clinical-stage failure. In parallel, many well-validated approaches for targeting CAMs with nanomedicine (NM) were reported over the years. A wide range of potential applications has been demonstrated in various preclinical studies, from drug delivery to the tumor vasculature, imaging of the inflamed endothelium, or blocking immune cells infiltration. However, no NM drug candidate emerged further into clinical development. In this review, we will summarize the most advanced examples of CAM-targeted NMs and juxtapose them with known traditional drugs against CAMs, in an attempt to identify important translational hurdles. Most importantly, we will summarize the proposed strategies to enhance endothelial CAM targeting by NMs, in an attempt to offer a catalog of tools for further development.

Cite

CITATION STYLE

APA

Milošević, N., Rütter, M., & David, A. (2022). Endothelial Cell Adhesion Molecules- (un)Attainable Targets for Nanomedicines. Frontiers in Medical Technology. Frontiers Media S.A. https://doi.org/10.3389/fmedt.2022.846065

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free